Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    FDA Approves Tapentadol for Relief of Moderate to Severe Acute Pain - (DGNews)
    Infection-Related Deaths Reported With Alemtuzumab, Warns Health Canada - (DGNews)
    Model Predicts Outcomes of Pegylated Interferon Therapy in Patients With Chronic Hepatitis B: Presented at AASLD - (DGDispatch)
    Long-Term Erythromycin Therapy Reduces COPD Exacerbations, but Raises Concerns - (DGNews)
    FDA Approves Eltrombopag for the Treatment of Chronic Immune Thrombocytopenic Purpura - (DGNews)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
      Asthma Treatment Guidelines and Use of Inhalers
      Use of Probiotics in the Management of Antibiotic-associated Diarrhea
      Antiplatelet Agents in the Prevention of Atherothrombotic Events
      Limiting GERD Progression in Older Patients: Reducing Costs Through Optimal Management
      New Guidelines for the Diagnosis and Management of Asthma

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Is Enoxaparin Injection from the Abdominal Wall Safe in Elderly People?: A Fatal Case of Rectus Sheath Hematoma
        Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
        Massive Pulmonary Emboli Associated with Olanzapine
        Exacerbation of Hepatitis C Induced Subclinical Hypoadrenalism by Interferon-Alpha2beta: A Case Report
        Complete Clinical Response of Metastatic Hepatocellular Carcinoma to Sorafenib in a Patient with Hemochromatosis: A Case Report

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Etanercept Has Similar Pharmacokinetics In Ankylosing Spondylitis As In Rheumatoid Arthritis: Presented at ACCP

        By Mike Fillon

        TAMPA, FL -- October 6, 2003 -- According to a new study, etanercept may benefit ankylosing spondylitis patients as much as those with rheumatoid arthritis. The poster study was presented here on September 21st at the 32nd Annual Meeting of the American College of Clinical Pharmacology (ACCP).

        Ankylosing spondylitis, or AS, is a chronic inflammatory disease characterised by axial skeletal ankylosis, inflammation at the insertions of tendons and occasionally peripheral arthritis. It occurs primarily in men and produces pain and stiffness due to inflammation of the sacroiliac, intervertibral and costovertebral joints.

        In the multicentre, double-blind, parallel, placebo-controlled randomised study, 43 eligible AS patients received 25 mg etanercept or placebo twice weekly for 12 weeks. Serum samples were collected at weeks four and 12. The median age of the subjects was 45 years, and their median body weight was 75 kg. Most of the subjects were male (79%), and 93% were Caucasian.

        A final covariate population pharmacokinetic (PK) model was developed based on the etanercept data from 265 rheumatoid arthritis patients and healthy subjects who received either intravenous or subcutaneous etanercept in 10 previous clinical studies. This model was used to predict the Bayesian-estimated etanercept PK parameters in AS patients from the current trial.

        "Based on the assumption that the AS disease state would not result in significantly different PK from those in patients with RA [rheumatoid arthritis]," said lead researcher Honghui Zhou, PhD, "the current data set was merged with the data used to obtain post hoc estimates of PK parameters of etanercept in AS patients. Whether or not the presence of AS had significant impact on the PK parameters of etanercept was tested in the model."

        No improvement in objective function value (OFV) was observed when AS was incorporated, which, according to Dr. Zhou, suggested no significant difference was expected in PK between patients with rheumatoid arthritis and those with AS. Based on a typical 45 year old 75 kg man, the mean Bayesian-predicted etanercept clearance in AS patients was estimated to be 0.072 L/h, and the steady-state trough concentration was estimated to be 2004 ng/mL. For rheumatoid arthritis patients, the clearance was 0.066 L/h and steady-state trough concentration was and 2069 ng/mL.

        Funding for the study was provided by Wyeth Research, Collegeville, Pennsylvania.


        [Study title: Pharmcokinetics Of Etanercept in Ankylosing Spondylitis Patients: A Population-Based Investigation.]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send